Soleno Therapeutics Inc
SLNO80.320USD
-8.170-9.23%
Close 07/10, 16:00（ET）Quotes delayed by 15 min
3.67BMarket Cap
LossP/E TTM
More Details of Soleno Therapeutics Inc Company
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Company Info
Ticker SymbolSLNO
Company nameSoleno Therapeutics Inc
IPO dateOct 23, 2014
Founded at1999
CEODr. Anish Bhatnagar, M.D.
Number of employees92
Security typeOrdinary Share
Fiscal year-endOct 23
Address100 Marine Parkway, Suite 400
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94065
Phone16502138444
Websitehttps://soleno.life/
Ticker SymbolSLNO
IPO dateOct 23, 2014
Founded at1999
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+61.40%
Ms. Patricia C. Hirano
Ms. Patricia C. Hirano
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
6.81K
-36.00%
Dr. Anish Bhatnagar, M.D.
Dr. Anish Bhatnagar, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Meredith Manning
Ms. Meredith Manning
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.20%
Vivo Capital, LLC
8.85%
Adage Capital Management, L.P.
8.72%
Avoro Capital Advisors LLC
5.01%
T. Rowe Price Associates, Inc.
4.70%
Other
62.53%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.20%
Vivo Capital, LLC
8.85%
Adage Capital Management, L.P.
8.72%
Avoro Capital Advisors LLC
5.01%
T. Rowe Price Associates, Inc.
4.70%
Other
62.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
33.33%
Hedge Fund
31.65%
Investment Advisor
26.64%
Venture Capital
12.54%
Private Equity
4.02%
Research Firm
2.73%
Individual Investor
1.92%
Bank and Trust
0.53%
Pension Fund
0.18%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
375
57.23M
113.56%
+142.75K
2025Q1
373
57.15M
113.59%
-442.82K
2024Q4
313
53.26M
117.76%
+3.04M
2024Q3
277
49.14M
121.09%
-377.00K
2024Q2
234
44.76M
117.95%
+4.14M
2024Q1
189
36.54M
114.10%
-1.05M
2023Q4
146
32.09M
102.81%
+3.37M
2023Q3
107
21.08M
166.08%
+14.34M
2023Q2
87
5.70M
63.31%
-1.46M
2023Q1
121
4.63M
57.04%
-249.13K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
5.14M
10.2%
-47.37K
-0.91%
Mar 31, 2025
Vivo Capital, LLC
4.46M
8.85%
-1.83M
-29.14%
Mar 31, 2025
Adage Capital Management, L.P.
4.39M
8.72%
+1.62M
+58.24%
Mar 31, 2025
Avoro Capital Advisors LLC
2.52M
5.01%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.37M
4.7%
+768.45K
+48.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.12M
4.21%
+1.36M
+179.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
3.69%
-18.21K
-0.97%
Mar 31, 2025
Nantahala Capital Management, LLC
1.76M
3.49%
-2.17M
-55.28%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
3.4%
-105.47K
-5.79%
Mar 31, 2025
Citadel Advisors LLC
1.58M
3.13%
+603.63K
+62.08%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Harbor Health Care ETF
2.39%
Invesco Dorsey Wright SmallCap Momentum ETF
2.19%
SPDR S&P Biotech ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
Direxion Daily S&P Biotech Bull 3X Shares
0.5%
JPMorgan Healthcare Leaders ETF
0.44%
First Trust Multi-Manager Small Cap Opportunities ETF
0.3%
Fidelity Fundamental Small-Mid Cap ETF
0.21%
Optimize Strategy Index ETF
0.19%
BNY Mellon US Small Cap Core Equity ETF
0.15%
View more
Harbor Health Care ETF
Proportion2.39%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion2.19%
SPDR S&P Biotech ETF
Proportion1.04%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.98%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.5%
JPMorgan Healthcare Leaders ETF
Proportion0.44%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.3%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.21%
Optimize Strategy Index ETF
Proportion0.19%
BNY Mellon US Small Cap Core Equity ETF
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Date
Type
Ratio
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
